Dianthus Therapeutics (NASDAQ:DNTH) Posts Earnings Results, Misses Expectations By $0.46 EPS

Dianthus Therapeutics (NASDAQ:DNTH) announced its quarterly earnings results on Monday. The company reported ($1.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.97) by ($0.46), FiscalAI reports. The business had revenue of $0.57 million during the quarter, compared to the consensus estimate of $0.40 million. Dianthus Therapeutics had a negative return on equity of 33.02% and a negative net margin of 4,106.04%.

Dianthus Therapeutics Price Performance

Shares of NASDAQ:DNTH traded up $17.80 during midday trading on Monday, hitting $83.00. The company had a trading volume of 2,527,468 shares, compared to its average volume of 851,573. The company has a market cap of $3.59 billion, a price-to-earnings ratio of -23.85 and a beta of 1.56. The company has a fifty day moving average of $48.42 and a two-hundred day moving average of $40.78. Dianthus Therapeutics has a 12-month low of $13.36 and a 12-month high of $84.86.

Institutional Investors Weigh In On Dianthus Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Dianthus Therapeutics by 4.2% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,334 shares of the company’s stock worth $280,000 after purchasing an additional 618 shares in the last quarter. American Century Companies Inc. boosted its holdings in shares of Dianthus Therapeutics by 13.2% in the 2nd quarter. American Century Companies Inc. now owns 54,140 shares of the company’s stock valued at $1,009,000 after acquiring an additional 6,323 shares during the last quarter. Invesco Ltd. increased its stake in shares of Dianthus Therapeutics by 31.1% in the second quarter. Invesco Ltd. now owns 20,940 shares of the company’s stock worth $390,000 after acquiring an additional 4,962 shares during the period. Alliancebernstein L.P. raised its holdings in shares of Dianthus Therapeutics by 14.5% during the second quarter. Alliancebernstein L.P. now owns 1,174,822 shares of the company’s stock worth $21,887,000 after purchasing an additional 149,200 shares during the last quarter. Finally, Raymond James Financial Inc. acquired a new position in Dianthus Therapeutics during the second quarter valued at $27,000. Institutional investors own 47.53% of the company’s stock.

Trending Headlines about Dianthus Therapeutics

Here are the key news stories impacting Dianthus Therapeutics this week:

• Positive Sentiment: Early GO decision in Phase 3 CAPTIVATE — Dianthus announced an early “GO” decision following an interim responder analysis: the trial hit the GO criteria of 20 confirmed responders with fewer than 40 planned Part A completers. The company will keep the Part A dose at 300mg/2mL S.C. Q2W and plans to engage regulators about removing the 600mg/4mL option — a substantive clinical/regulatory de‑risking step for claseprubart. Article Title
• Positive Sentiment: Analyst upgrade / price-target lift — Truist raised its price target from $63 to $110 and maintained a “buy” rating, signalling increased upside expectations and likely supporting buying interest. Article Title
• Neutral Sentiment: Investor access / upcoming commentary — Dianthus hosted (and scheduled) a conference call and webcast to discuss the interim responder analysis results, which should provide additional color and could drive intraday volatility depending on management tone and Q&A. Article Title
• Neutral Sentiment: Market commentary / valuation focus — Recent write-ups evaluate DNTH after a strong run-up in the share price; these pieces can amplify debate on whether current valuation already prices the program successes. Article Title
• Negative Sentiment: Q4 earnings miss and widening loss — Dianthus reported Q4 EPS of ($1.43) vs. consensus (~$0.97 loss), missing estimates by ~$0.46; revenue was $0.57M (above an estimate of $0.40M) but the company posted extremely negative margins and ROE. The larger-than-expected loss raises near-term profitability concerns and could limit upside despite the clinical news. Article Title

Analysts Set New Price Targets

A number of research firms have commented on DNTH. Truist Financial upped their price target on Dianthus Therapeutics from $63.00 to $110.00 and gave the company a “buy” rating in a research report on Monday. Jefferies Financial Group lifted their price objective on shares of Dianthus Therapeutics from $66.00 to $81.00 and gave the stock a “buy” rating in a report on Monday, February 2nd. Wedbush increased their price target on shares of Dianthus Therapeutics from $46.00 to $55.00 and gave the company an “outperform” rating in a research report on Wednesday, February 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of Dianthus Therapeutics in a research report on Wednesday, January 21st. Finally, HC Wainwright raised their price objective on shares of Dianthus Therapeutics from $40.00 to $47.00 and gave the company a “buy” rating in a research report on Monday, November 10th. Nine analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $73.50.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.